1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Vizionfocus Inc.

Vizionfocus Inc.

4771.TW
Vizionfocus Inc.TW flagTaiwan Stock Exchange
213.00
TWD
+1.00
- -
12.50BMarket Cap
Vizionfocus Inc.
4771.TW
(Taiwan Stock Exchange)

Recent

price

213.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
9.3
12.1
17.17
28.11
35.27
49.29
52.94
- -
59.97
Revenue per Share
0.04
2.49
2.94
4.64
6.02
10.77
11.81
- -
12.74
Basic EPS, GAAP
-5.08
-7.52
-6.3
-1.02
8.95
-8.34
3.48
- -
-2.37
Free Cash Flow per Basic Share
- -
- -
- -
- -
1.5
2.49
3.3
- -
- -
Dividend per Share
3.99
7.93
10.73
15.54
18.65
20.84
28.1
- -
33.6
Book Value per Share
13.42
20.65
25.56
35.35
37.82
37.46
65.9
- -
73.07
Tangible Book Value per Share
34
48
50
51
52
52
57
- -
58
Basic Weighted Avg Shares
315
585
855
1,420
1,834
2,572
3,002
3,487
3,487
Sales/Revenue/Turnover
-3.32
13.8
19.03
21.73
26.52
28.48
29.05
28.8
28.8
Operating Margin (%)
42
80
138
169
234
279
355
409
409
Depreciation Expense
1
120
146
234
313
562
670
741
741
Net Income, GAAP
- -
- -
- -
15.65
17.01
21.42
20.79
19.96
19.96
Effective Tax Rate (%)
0.43
20.57
17.12
16.49
17.06
21.86
22.3
21.24
21.24
Profit Margin (%)
185
427
616
864
1,026
803
1,621
1,614
1,614
Working Capital
- -
368
635
601
615
1,376
1,131
1,375
1,375
LT Debt
466
1,015
1,293
1,809
2,022
2,036
3,850
4,409
4,409
Total Equity
- -
- -
- -
11.18
14.94
17.42
15.23
14.2
14.2
Return on Invested Capital (%)
- -
- -
- -
11.27
15.71
18.7
20.06
19.27
19.27
Return on Capital (%)
- -
46.38
31.88
35.48
35.67
54.66
49.96
41.77
41.77
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
197
198
212
LT Borrowings
895
1,174
1,115
LT Finance Leases
270
264
260
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
58
59
59
Market Capitalization
10,551
10,409
10,060

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
2,607
2,643
2,658
Cash, Cash Equivalents & STI
1,546
1,514
1,289
Accounts Receivable, Net
671
699
880
Inventories
290
335
361
Total Current Liabilities
1,224
826
1,044
Payables & Accruals
- -
- -
- -
ST Debt
197
198
212
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
31.19%
14.52%
Free Cash Flow
- -
-318.91%
-169.84%
Net Income, GAAP
- -
40.6%
10.63%
Sales/Revenue/Turnover
- -
33.67%
16.17%
Total Cash Common Dividend
- -
- -
72.3%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
509
553
704
807
2,572
2024
768
730
742
762
3,002
2025
811
872
854
951
3,487

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1.74
2.24
3.28
- -
10.77
2024
3.42
3
2.5
- -
11.81
2025
3.32
2.58
3.3
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.49
2024
- -
- -
- -
- -
3.3
2025
- -
- -
- -
- -
- -
Similar Companies
Meihua International Medical Technologies Co., Ltd. (MHUAF)
Andon Health Co., Ltd. (002432.SZ)
Ligua Inc. (7090.T)
PlexBio Co., Ltd. (6572.TWO)
Qatari German Company for Medical Devices (Q.P.S.C.) (QGMD.QA)
Bionime Corporation (4737.TW)
Business
Vizionfocus Inc. (4771.TW) manufactures and sells soft disposable contact lenses, including daily, bi-weekly, and monthly replacement types with 38% and 55% moisture content; the company offers spherical (myopia/hyperopia), toric, multifocal, color/tinted, blue light blocking, and silicone hydrogel lenses, such as performance-tinted multifocal (ocufilcon D), B12+HA, menthol-infused highly moist materials, and second-generation blue light blocking variants; it also provides research, design, development, and wholesale services for optical instruments and medical equipment. Founded in 2012 and headquartered in Zhunan Township, Miaoli County, Taiwan, Vizionfocus operates factories in Taiwan (Zhunan headquarters and second factory) and Jiangsu Danyang, China, with monthly production capacity exceeding 57 million pieces as of 2025; the company serves markets in Japan (54% of 2024 revenue), China (41%), the United States, Taiwan, Southeast Asia, and Europe through 55 product licenses and quality certifications including ISO 13485, CE MDD, Japan QMS, and China systems. Recent developments include the 2024 launch of toric, multifocal, and second-generation blue light blocking lenses; expansion of silicone hydrogel color lenses with DK/t 100 and surface hydrophilic treatment; new offerings in China such as SiHy series and 6-month replacement colored contacts; a resolved patent infringement lawsuit with Pegavision in September 2025; and plans for a new headquarters in Zhunan, Taiwan, in 2026 alongside capacity buildup and market share growth in differentiated products.